U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364513) titled 'Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies' on Jan. 13.
Brief Summary: Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.
Study Start Date: Jan. 12
Study Type: INTERVENTIONAL
Condition:
Type 1 Interferonopathies
Intervention:
DRUG: IMSB301
Twice daily administration for 28 days.
Subjects will be treated as out-patient and will return to the clinic at least once weekly on Days 8, 15, 22 and 29.
Continued treatment beyond Day 28 may be considered on a case-by-case basis for subjects benefiting from treatment.
Recruitment Status: RECRUITING
Sponsor: ImmuneSensor ...